Skip to content

Novavax NVAX Payments for finance leases

Payments for finance leases at other companies

Roivant Sciences logo
Roivant SciencesROIV
$0
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
$13K
BioCryst Pharmaceuticals logo
BioCryst PharmaceuticalsBCRX
$345K-33.1%
LQD
Liquidia CorporationLQDA
$0-100%

Other financials

Income statement

See full
Revenue$139.5M-79.1%
Gross profit$108.8M-83.3%
Operating income-$15.4M-103%
Net income-$9.5M-102%
EPS (diluted)-$0.06-102%

Balance sheet

See full
Cash & equivalents$228.4M-13.3%
Total debt$295.1M+404%
Total equity-$144.8M-91.4%
Total assets$1.0B-19.3%

Cash flow

See full
Operating cash flow-$32.4M+82.5%
CapEx$1.3M-20.4%
Free cash flow-$33.7M+82.0%

Valuation

See full
Market cap$1.46B+41.0%
Enterprise value$1.53B+83.6%
P/S2.5×+1.6×

Profitability

See full
Gross margin85%-2.5pp
Operating margin-13.1%-45.9pp
Net margin-14.7%-52.9pp
FCF margin-58.9%-61.4pp

Returns & leverage

See full
Return on equity-238.6%
Debt / equity1.5×
Current ratio2.5×+0.4×

Where this comes from

Reported directly by Novavax in its filing.

Tagged under the XBRL concept us-gaap:FinanceLeasePrincipalPayments.

The official record: Novavax’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Novavax's payments for finance leases.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Novavax's payments for finance leases?
Novavax (NVAX) reported payments for finance leases of $578K in Q1 2026.
How has Novavax's payments for finance leases changed year-over-year?
Novavax's payments for finance leases decreased by 73.7% year-over-year, from $2.2M to $578K.
What is the long-term trend for Novavax's payments for finance leases?
Over 4 years (2021 to 2025), Novavax's payments for finance leases has grown at a -47.0% compound annual growth rate (CAGR), from $127.91M to $10.07M.
What does payments for finance leases mean?
Principal payments on finance lease obligations, reducing the lease liability on the balance sheet.